In the CASTLE study, lower response rates were observed in patients with baseline HIV-RNA ≥100,000 copies/mL in both arms and were associated with lower baseline CD4 cell count for LPV/r but not ATV/r.
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Methods
Randomized, open-label, prospective study comparing once-daily ATV/r with twice-daily LPV/r, both with fixeddose TDF/FTC in 883 treatment-naive patients. Treatment outcomes of HIV-RNA <50 c/mL at week 48 using confirmed virologic response (CVR) and grade 2-4 treatmentrelated AEs through week 48 are presented by pre-specified baseline HIV-RNA and CD4 cell count strata.
Summary of results
The proportion of responders (CVR HIV-RNA <50 c/mL, ITT) at week 48 by baseline HIV RNA strata (<100,000, 100,000-<500,000, and ≥500,000) were 83%, 76%, and 64% for ATV/r and 80%, 74%, and 61% for LPV/r (Table  1 ).
In patients with both baseline CD4 <100 and HIV-RNA ≥100,000, 60/83 (72%) on ATV/r and 40/64 (63%) on LPV/r achieved HIV RNA <50 c/mL (CVR, ITT). Incidence of grades 2-4 treatment-related AEs through week 48 by baseline HIV-RNA strata (<100,000, 100,000-<500,000, and ≥500,000) were 29%, 26%, and 15% for ATV/r; and 31%, 27%, and 30% for LPV/r. (Table 2 <supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts -A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement> This abstract is available from: http://www.jiasociety.org/content/11/S1/P8 © 2008 Uy et al; licensee BioMed Central Ltd. 
ATV/r LPV/r
As-Randomized <50 50-<100 100-<200 ≥200 <50 50-<100 100-<200 ≥200
ITT n = 58 n = 45 n = 106 n = 222 n = 48 n = 29 n = 134 n = 228
Responder 45 (78) 34 (76) 80 (75) 178 (80) 30 (63) 20 (69) 104 (78) 182 (80) Virologic failure* 7 (12) 7 (16) 17 (16) 26 (12) 6 (13) 7 (24) 13 (10) 24 (11) Discontinued 6 (10) 4 (9) 9 (8) 16 (7) 12 (25) 2 (7) 16 (12) *Includes never suppressed and on study through week 48, discontinued due to insufficient viral load response through week 48, and rebound without resuppression.
Conclusion
Lower response rates at higher baseline HIV-RNA were seen for both ATV/r and LPV/r. The trend for lower response rates at lower baseline CD4 cell counts for LPV/ r observed in the ITT analysis did not appear to be present in the on-treatment analysis. ATV/r and LPV/r had consistent adverse event (AE) profiles within each arm by baseline HIV-RNA. More AEs, most commonly diarrhea and nausea, were observed with LPV/r at low baseline CD4 cell counts. 
ATV/r LPV/r
As-treated <50 50-<100 100-<200 ≥200 <50 50-<100 100-<200 ≥200 n = 59 n = 45 n = 106 n = 222 n = 47 n = 29 n = 133 n = 224 Any 12 (20) 9 (20) 22 (21) 71 (32) 19 (40) 7 (24) 35 (26) 65 (29) Jaundice 1 (2) 0 2 (2) 12 (5) 0 0 0 0 Diarrhea 0 1 (2) 3 (3) 6 (3) 8 (17) 3 (10) 12 (9) 26 (12) Nausea 2 (3) 0 6 (6) 9 (4) 5 (11) 2 (7) 9 (7) 16 (7) 
